Review



anti human cd45 pe  (Biogems International)


Bioz Verified Symbol Biogems International is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Biogems International anti human cd45 pe
    Anti Human Cd45 Pe, supplied by Biogems International, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/Anti-Human+CD45+PE/us12594341-637-0-2
    Average 94 stars, based on 1 article reviews
    anti human cd45 pe - by Bioz Stars, 2026-08
    94/100 stars

    Images



    Similar Products

    94
    Guangzhou JET Bio-Filtration pe anti-human cd45 antibody
    Pe Anti Human Cd45 Antibody, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/PE+Anti-Human+CD45+Antibody/custom%40e-ab-f1137d%4042297766
    Average 94 stars, based on 1 article reviews
    pe anti-human cd45 antibody - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec anti human cd45 antibody conjugated with pe
    Positive and negative control cells for both marker panels. ( A ) HeLa (white arrows): in the first panel positive for cytokeratin (CK), Vimentin (Vim), VEGF and in the second panel positive for p16INK4A, negative for PD-L1 and <t>CD45.</t> ( B ) T98G (red arrows): positive for Vim. ( C ) CaSki (yellow arrows): positive for CK, Vim, VEGF, PD-L1 and p16INK4A. ( D ) MCF-7 (green arrows): positive for CK. All cell lines were negative for CD45. Only hematopoietic cells showed <t>CD45</t> <t>positive</t> staining. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and the figure was assembled using Microsoft PowerPoint.
    Anti Human Cd45 Antibody Conjugated With Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/CD45+Antibody%2C+anti-human%2C+REAfinity/pmc13256168-360-35-44
    Average 96 stars, based on 1 article reviews
    anti human cd45 antibody conjugated with pe - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    94
    Biogems International anti human cd45 pe
    Positive and negative control cells for both marker panels. ( A ) HeLa (white arrows): in the first panel positive for cytokeratin (CK), Vimentin (Vim), VEGF and in the second panel positive for p16INK4A, negative for PD-L1 and <t>CD45.</t> ( B ) T98G (red arrows): positive for Vim. ( C ) CaSki (yellow arrows): positive for CK, Vim, VEGF, PD-L1 and p16INK4A. ( D ) MCF-7 (green arrows): positive for CK. All cell lines were negative for CD45. Only hematopoietic cells showed <t>CD45</t> <t>positive</t> staining. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and the figure was assembled using Microsoft PowerPoint.
    Anti Human Cd45 Pe, supplied by Biogems International, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/Anti-Human+CD45+PE/us12594341-637-0-2
    Average 94 stars, based on 1 article reviews
    anti human cd45 pe - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology cd45
    Positive and negative control cells for both marker panels. ( A ) HeLa (white arrows): in the first panel positive for cytokeratin (CK), Vimentin (Vim), VEGF and in the second panel positive for p16INK4A, negative for PD-L1 and <t>CD45.</t> ( B ) T98G (red arrows): positive for Vim. ( C ) CaSki (yellow arrows): positive for CK, Vim, VEGF, PD-L1 and p16INK4A. ( D ) MCF-7 (green arrows): positive for CK. All cell lines were negative for CD45. Only hematopoietic cells showed <t>CD45</t> <t>positive</t> staining. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and the figure was assembled using Microsoft PowerPoint.
    Cd45, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/PE+Anti-Human+CD34+Antibody/pm41905456-82-16-24
    Average 94 stars, based on 1 article reviews
    cd45 - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd45 pe
    Expression of CD68 and CD163 in ccRCC samples. (A) CD68 was assessed using immunohistochemistry. (B) Expression of CD68 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). (C) CD163 was assessed using immunohistochemistry. (D) Expression of CD163 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). Student’s t-test for two groups and one-way ANOVA for four groups; *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. (E) Multiplex immunofluorescence imaging of ccRCC tumor tissues (representative of three patients) depicting CK (cytokeratin), CD163 and CD68 expression. White bar represents 200 μm (left) and 10 μm (right). (F) UMAP depicting clusters of single-cell data showing the expression of CD68 and CD163. Cell type annotations were adopted from the original publication . (G) Fraction of CD68+ cells co-expressing CD163 in RCC tumor tissue macrophage population. Positivity in scRNA-seq for CD68 and CD163 was defined from raw UMI counts as ≥1 UMI per gene (F) . (H) Flow cytometric analysis of <t>CD45</t> on cells from central and peripheral ccRCC tumor tissue and adjacent kidney. (I) As in (H) , analysis of CD163 on CD68+ cells from central and peripheral ccRCC tumor tissue and adjacent kidney. Values were normalized to kidney controls. Representative histogram with geometric mean fluorescence intensities on the right. One-way ANOVA with Dunnett post-test comparing to kidney. *p<0.05, **p<0.01, ***p<0.001. (J) Data from (I) , tumor periphery, plotted as individual patients, depicting the portion of CD163+ and CD163neg cells.
    Cd45 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/CD45+Antibody%2C+anti-human/pmc12989337-87-22-41
    Average 96 stars, based on 1 article reviews
    cd45 pe - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    93
    Proteintech anti fluorochrome-conjugated
    Expression of CD68 and CD163 in ccRCC samples. (A) CD68 was assessed using immunohistochemistry. (B) Expression of CD68 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). (C) CD163 was assessed using immunohistochemistry. (D) Expression of CD163 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). Student’s t-test for two groups and one-way ANOVA for four groups; *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. (E) Multiplex immunofluorescence imaging of ccRCC tumor tissues (representative of three patients) depicting CK (cytokeratin), CD163 and CD68 expression. White bar represents 200 μm (left) and 10 μm (right). (F) UMAP depicting clusters of single-cell data showing the expression of CD68 and CD163. Cell type annotations were adopted from the original publication . (G) Fraction of CD68+ cells co-expressing CD163 in RCC tumor tissue macrophage population. Positivity in scRNA-seq for CD68 and CD163 was defined from raw UMI counts as ≥1 UMI per gene (F) . (H) Flow cytometric analysis of <t>CD45</t> on cells from central and peripheral ccRCC tumor tissue and adjacent kidney. (I) As in (H) , analysis of CD163 on CD68+ cells from central and peripheral ccRCC tumor tissue and adjacent kidney. Values were normalized to kidney controls. Representative histogram with geometric mean fluorescence intensities on the right. One-way ANOVA with Dunnett post-test comparing to kidney. *p<0.05, **p<0.01, ***p<0.001. (J) Data from (I) , tumor periphery, plotted as individual patients, depicting the portion of CD163+ and CD163neg cells.
    Anti Fluorochrome Conjugated, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/PE+Anti-human+CD45/pm41684277-112-20-24
    Average 93 stars, based on 1 article reviews
    anti fluorochrome-conjugated - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    93
    Proteintech anti hcd45 pe
    Expression of CD68 and CD163 in ccRCC samples. (A) CD68 was assessed using immunohistochemistry. (B) Expression of CD68 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). (C) CD163 was assessed using immunohistochemistry. (D) Expression of CD163 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). Student’s t-test for two groups and one-way ANOVA for four groups; *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. (E) Multiplex immunofluorescence imaging of ccRCC tumor tissues (representative of three patients) depicting CK (cytokeratin), CD163 and CD68 expression. White bar represents 200 μm (left) and 10 μm (right). (F) UMAP depicting clusters of single-cell data showing the expression of CD68 and CD163. Cell type annotations were adopted from the original publication . (G) Fraction of CD68+ cells co-expressing CD163 in RCC tumor tissue macrophage population. Positivity in scRNA-seq for CD68 and CD163 was defined from raw UMI counts as ≥1 UMI per gene (F) . (H) Flow cytometric analysis of <t>CD45</t> on cells from central and peripheral ccRCC tumor tissue and adjacent kidney. (I) As in (H) , analysis of CD163 on CD68+ cells from central and peripheral ccRCC tumor tissue and adjacent kidney. Values were normalized to kidney controls. Representative histogram with geometric mean fluorescence intensities on the right. One-way ANOVA with Dunnett post-test comparing to kidney. *p<0.05, **p<0.01, ***p<0.001. (J) Data from (I) , tumor periphery, plotted as individual patients, depicting the portion of CD163+ and CD163neg cells.
    Anti Hcd45 Pe, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/PE+Anti-human+CD45/pm41684277-112-22-24
    Average 93 stars, based on 1 article reviews
    anti hcd45 pe - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology china 、pe cd90
    Expression of CD68 and CD163 in ccRCC samples. (A) CD68 was assessed using immunohistochemistry. (B) Expression of CD68 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). (C) CD163 was assessed using immunohistochemistry. (D) Expression of CD163 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). Student’s t-test for two groups and one-way ANOVA for four groups; *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. (E) Multiplex immunofluorescence imaging of ccRCC tumor tissues (representative of three patients) depicting CK (cytokeratin), CD163 and CD68 expression. White bar represents 200 μm (left) and 10 μm (right). (F) UMAP depicting clusters of single-cell data showing the expression of CD68 and CD163. Cell type annotations were adopted from the original publication . (G) Fraction of CD68+ cells co-expressing CD163 in RCC tumor tissue macrophage population. Positivity in scRNA-seq for CD68 and CD163 was defined from raw UMI counts as ≥1 UMI per gene (F) . (H) Flow cytometric analysis of <t>CD45</t> on cells from central and peripheral ccRCC tumor tissue and adjacent kidney. (I) As in (H) , analysis of CD163 on CD68+ cells from central and peripheral ccRCC tumor tissue and adjacent kidney. Values were normalized to kidney controls. Representative histogram with geometric mean fluorescence intensities on the right. One-way ANOVA with Dunnett post-test comparing to kidney. *p<0.05, **p<0.01, ***p<0.001. (J) Data from (I) , tumor periphery, plotted as individual patients, depicting the portion of CD163+ and CD163neg cells.
    China 、Pe Cd90, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/FITC+Anti-Human+CD45+Antibody/pm41649774-150-28-29
    Average 94 stars, based on 1 article reviews
    china 、pe cd90 - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    94
    R&D Systems cd45 pe r d systems
    Expression of CD68 and CD163 in ccRCC samples. (A) CD68 was assessed using immunohistochemistry. (B) Expression of CD68 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). (C) CD163 was assessed using immunohistochemistry. (D) Expression of CD163 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). Student’s t-test for two groups and one-way ANOVA for four groups; *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. (E) Multiplex immunofluorescence imaging of ccRCC tumor tissues (representative of three patients) depicting CK (cytokeratin), CD163 and CD68 expression. White bar represents 200 μm (left) and 10 μm (right). (F) UMAP depicting clusters of single-cell data showing the expression of CD68 and CD163. Cell type annotations were adopted from the original publication . (G) Fraction of CD68+ cells co-expressing CD163 in RCC tumor tissue macrophage population. Positivity in scRNA-seq for CD68 and CD163 was defined from raw UMI counts as ≥1 UMI per gene (F) . (H) Flow cytometric analysis of <t>CD45</t> on cells from central and peripheral ccRCC tumor tissue and adjacent kidney. (I) As in (H) , analysis of CD163 on CD68+ cells from central and peripheral ccRCC tumor tissue and adjacent kidney. Values were normalized to kidney controls. Representative histogram with geometric mean fluorescence intensities on the right. One-way ANOVA with Dunnett post-test comparing to kidney. *p<0.05, **p<0.01, ***p<0.001. (J) Data from (I) , tumor periphery, plotted as individual patients, depicting the portion of CD163+ and CD163neg cells.
    Cd45 Pe R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+cd45+pe/Human+Mesenchymal+Stem+Cell+Multi-Color+Flow+Kit/us12527868-798-16-18
    Average 94 stars, based on 1 article reviews
    cd45 pe r d systems - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    Image Search Results


    Positive and negative control cells for both marker panels. ( A ) HeLa (white arrows): in the first panel positive for cytokeratin (CK), Vimentin (Vim), VEGF and in the second panel positive for p16INK4A, negative for PD-L1 and CD45. ( B ) T98G (red arrows): positive for Vim. ( C ) CaSki (yellow arrows): positive for CK, Vim, VEGF, PD-L1 and p16INK4A. ( D ) MCF-7 (green arrows): positive for CK. All cell lines were negative for CD45. Only hematopoietic cells showed CD45 positive staining. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and the figure was assembled using Microsoft PowerPoint.

    Journal: International Journal of Molecular Sciences

    Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

    doi: 10.3390/ijms27114875

    Figure Lengend Snippet: Positive and negative control cells for both marker panels. ( A ) HeLa (white arrows): in the first panel positive for cytokeratin (CK), Vimentin (Vim), VEGF and in the second panel positive for p16INK4A, negative for PD-L1 and CD45. ( B ) T98G (red arrows): positive for Vim. ( C ) CaSki (yellow arrows): positive for CK, Vim, VEGF, PD-L1 and p16INK4A. ( D ) MCF-7 (green arrows): positive for CK. All cell lines were negative for CD45. Only hematopoietic cells showed CD45 positive staining. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and the figure was assembled using Microsoft PowerPoint.

    Article Snippet: In the second round of immunofluorescence staining, anti-human PD-L1 conjugated with AF 647 antibody (Cat. No. ab209960, abcam, Cambridge, UK), anti-human p16INK4a conjugated with AF488 antibody (Cat. No. ab199756, abcam, Cambridge, UK), and, for counterstaining, anti-human CD45 antibody conjugated with PE (Cat. No. 130-110-770, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied, followed by image acquisition using the excitation filters mentioned above.

    Techniques: Negative Control, Marker, Staining, Software

    Representative images of patient-derived DTCs with three different profiles. ( A ) DTC positive for Vim, VEGF and p16, negative for CK, PD-L1 and CD45. ( B ) CK and Vim positive while negative for VEGF, PD-L1, p16 and CD45. ( C ) DTC positive for Vim and PD-L1, negative for all other markers. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and figure was assembled using Microsoft PowerPoint.

    Journal: International Journal of Molecular Sciences

    Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

    doi: 10.3390/ijms27114875

    Figure Lengend Snippet: Representative images of patient-derived DTCs with three different profiles. ( A ) DTC positive for Vim, VEGF and p16, negative for CK, PD-L1 and CD45. ( B ) CK and Vim positive while negative for VEGF, PD-L1, p16 and CD45. ( C ) DTC positive for Vim and PD-L1, negative for all other markers. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and figure was assembled using Microsoft PowerPoint.

    Article Snippet: In the second round of immunofluorescence staining, anti-human PD-L1 conjugated with AF 647 antibody (Cat. No. ab209960, abcam, Cambridge, UK), anti-human p16INK4a conjugated with AF488 antibody (Cat. No. ab199756, abcam, Cambridge, UK), and, for counterstaining, anti-human CD45 antibody conjugated with PE (Cat. No. 130-110-770, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied, followed by image acquisition using the excitation filters mentioned above.

    Techniques: Derivative Assay, Software

    Sequential multi-parameter immunofluorescent staining. After applying the first antibody panel (CK, Vim and VEGF), the slides were scanned and DTC profiles were assessed. Subsequently, releasable fluorochrome-conjugates were digested and the slides were subjected to the second antibody panel (PD-L1, p16, CD45) followed by scanning and DTC detection. Created with BioRender.com.

    Journal: International Journal of Molecular Sciences

    Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

    doi: 10.3390/ijms27114875

    Figure Lengend Snippet: Sequential multi-parameter immunofluorescent staining. After applying the first antibody panel (CK, Vim and VEGF), the slides were scanned and DTC profiles were assessed. Subsequently, releasable fluorochrome-conjugates were digested and the slides were subjected to the second antibody panel (PD-L1, p16, CD45) followed by scanning and DTC detection. Created with BioRender.com.

    Article Snippet: In the second round of immunofluorescence staining, anti-human PD-L1 conjugated with AF 647 antibody (Cat. No. ab209960, abcam, Cambridge, UK), anti-human p16INK4a conjugated with AF488 antibody (Cat. No. ab199756, abcam, Cambridge, UK), and, for counterstaining, anti-human CD45 antibody conjugated with PE (Cat. No. 130-110-770, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied, followed by image acquisition using the excitation filters mentioned above.

    Techniques: Staining

    CaSki cells before and after the release step. Representative immunofluorescence image of two CaSki cells spiked into bone marrow cells ( A ) before and ( B ) after the release step. The PE channel shows VEGF staining before staining with CD45, while nuclei were stained with DAPI (blue). Images were processed using Zeiss ZEN software and figure was assembled using Microsoft PowerPoint.

    Journal: International Journal of Molecular Sciences

    Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

    doi: 10.3390/ijms27114875

    Figure Lengend Snippet: CaSki cells before and after the release step. Representative immunofluorescence image of two CaSki cells spiked into bone marrow cells ( A ) before and ( B ) after the release step. The PE channel shows VEGF staining before staining with CD45, while nuclei were stained with DAPI (blue). Images were processed using Zeiss ZEN software and figure was assembled using Microsoft PowerPoint.

    Article Snippet: In the second round of immunofluorescence staining, anti-human PD-L1 conjugated with AF 647 antibody (Cat. No. ab209960, abcam, Cambridge, UK), anti-human p16INK4a conjugated with AF488 antibody (Cat. No. ab199756, abcam, Cambridge, UK), and, for counterstaining, anti-human CD45 antibody conjugated with PE (Cat. No. 130-110-770, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied, followed by image acquisition using the excitation filters mentioned above.

    Techniques: Immunofluorescence, Staining, Software

    Expression of CD68 and CD163 in ccRCC samples. (A) CD68 was assessed using immunohistochemistry. (B) Expression of CD68 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). (C) CD163 was assessed using immunohistochemistry. (D) Expression of CD163 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). Student’s t-test for two groups and one-way ANOVA for four groups; *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. (E) Multiplex immunofluorescence imaging of ccRCC tumor tissues (representative of three patients) depicting CK (cytokeratin), CD163 and CD68 expression. White bar represents 200 μm (left) and 10 μm (right). (F) UMAP depicting clusters of single-cell data showing the expression of CD68 and CD163. Cell type annotations were adopted from the original publication . (G) Fraction of CD68+ cells co-expressing CD163 in RCC tumor tissue macrophage population. Positivity in scRNA-seq for CD68 and CD163 was defined from raw UMI counts as ≥1 UMI per gene (F) . (H) Flow cytometric analysis of CD45 on cells from central and peripheral ccRCC tumor tissue and adjacent kidney. (I) As in (H) , analysis of CD163 on CD68+ cells from central and peripheral ccRCC tumor tissue and adjacent kidney. Values were normalized to kidney controls. Representative histogram with geometric mean fluorescence intensities on the right. One-way ANOVA with Dunnett post-test comparing to kidney. *p<0.05, **p<0.01, ***p<0.001. (J) Data from (I) , tumor periphery, plotted as individual patients, depicting the portion of CD163+ and CD163neg cells.

    Journal: Frontiers in Immunology

    Article Title: Increased expression of CD36 and CD163 in clear cell renal cell carcinoma suggests an association between lipid transport and an “M2-like” macrophage phenotype

    doi: 10.3389/fimmu.2026.1773666

    Figure Lengend Snippet: Expression of CD68 and CD163 in ccRCC samples. (A) CD68 was assessed using immunohistochemistry. (B) Expression of CD68 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). (C) CD163 was assessed using immunohistochemistry. (D) Expression of CD163 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). Student’s t-test for two groups and one-way ANOVA for four groups; *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. (E) Multiplex immunofluorescence imaging of ccRCC tumor tissues (representative of three patients) depicting CK (cytokeratin), CD163 and CD68 expression. White bar represents 200 μm (left) and 10 μm (right). (F) UMAP depicting clusters of single-cell data showing the expression of CD68 and CD163. Cell type annotations were adopted from the original publication . (G) Fraction of CD68+ cells co-expressing CD163 in RCC tumor tissue macrophage population. Positivity in scRNA-seq for CD68 and CD163 was defined from raw UMI counts as ≥1 UMI per gene (F) . (H) Flow cytometric analysis of CD45 on cells from central and peripheral ccRCC tumor tissue and adjacent kidney. (I) As in (H) , analysis of CD163 on CD68+ cells from central and peripheral ccRCC tumor tissue and adjacent kidney. Values were normalized to kidney controls. Representative histogram with geometric mean fluorescence intensities on the right. One-way ANOVA with Dunnett post-test comparing to kidney. *p<0.05, **p<0.01, ***p<0.001. (J) Data from (I) , tumor periphery, plotted as individual patients, depicting the portion of CD163+ and CD163neg cells.

    Article Snippet: Reagents and antibodies used included FcR Blocking Reagent (Cat# 130-059-901), CD36 PE (Cat# 130-110-877), CD147 APC (Cat# 130-124-295), CD8a PE (Cat# 130-117-201), CD45 PE (Cat# 130-113-118), CD68 PE (Cat# 130-128-345), CD163 PE (Cat# 130-127-908), and pan-Cytokeratin APC (Cat# 130-123-091), all from Miltenyi Biotec.

    Techniques: Expressing, Immunohistochemistry, Multiplex Assay, Immunofluorescence, Imaging, Single Cell, Fluorescence